QuadMedicine Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	13,112	9,304	1,012
Revenue Growth (YoY)	195.47%	819.58%	-
Gross Profit	13,112	9,304	1,012
Selling, General & Admin	1,618	1,337	1,413
Research & Development	16,399	12,269	9,006
Other Operating Expenses	6.57	2.75	2.91
Operating Expenses	18,079	13,753	10,531
Operating Income	-4,966	-4,449	-9,519
Interest Expense	-367.2	-370.45	-114.15
Interest & Investment Income	81.87	23.9	107.11
Currency Exchange Gain (Loss)	67.54	129.9	20.89
Other Non Operating Income (Expenses)	-302.75	-303.84	-249.92
EBT Excluding Unusual Items	-5,487	-4,970	-9,755
Gain (Loss) on Sale of Assets	1.52	1.52	-3.14
Pretax Income	-5,485	-4,968	-9,759
Net Income	-5,485	-4,968	-9,759
Net Income to Common	-5,485	-4,968	-9,759
Shares Outstanding (Basic)	9	9	9
Shares Outstanding (Diluted)	9	9	9
Shares Change (YoY)	6.13%	0.94%	-
EPS (Basic)	-592.68	-569.92	-1129.97
EPS (Diluted)	-592.68	-570.00	-1130.00
Free Cash Flow	-7,544	-2,214	-10,056
Free Cash Flow Per Share	-815.09	-253.98	-1164.44
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-37.88%	-47.82%	-940.90%
Profit Margin	-41.84%	-53.40%	-964.54%
Free Cash Flow Margin	-57.54%	-23.80%	-993.97%
EBITDA	-1,654	-1,297	-7,448
EBITDA Margin	-12.61%	-13.94%	-
D&A For EBITDA	3,312	3,153	2,071
EBIT	-4,966	-4,449	-9,519
EBIT Margin	-37.88%	-47.82%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.